Caption Management’s Silence Therapeutics SLN Stock Holding History
Bought
Maintained
Sold
Other funds holding SLN
SL
Caption Management's SLN Position: Q3 2026 in Review
Caption Management increased its Silence Therapeutics (SLN) stake by 219% in Q3 2026, buying an estimated $4.33M and bringing the position to 518,674 shares worth $5.67M. The position accounts for 0.02% of the portfolio, ranked #615.
Caption Management first reported a position in SLN in Q2 2026 and has held it in 2 quarters since. 92 funds tracked by Wall St. Rank hold SLN as of Q3 2026.
- Caption Management held 518,674 shares of Silence Therapeutics worth $5.67M as of Q3 2026.
- Caption Management bought 356,198 Silence Therapeutics shares in Q3 2026, an estimated $4.33M.
- Silence Therapeutics made up 0.02% of Caption Management's portfolio in Q3 2026, its #615 holding.
- Caption Management first reported a position in Silence Therapeutics in Q2 2026 and has held it in 2 quarters since.
- 92 funds tracked by Wall St. Rank held Silence Therapeutics as of Q3 2026.
Based on Caption Management's 13F filing for Q3 2026, filed 16 Nov 2026.